ROYSTON IVOR

SEC source: 0000950170-24-131479 · ownership.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,438

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0000950170-24-131479 · ownership.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 839,741

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0000950170-24-106031 · ownership.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,657

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0000950170-24-106031 · ownership.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 814,522

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0000950170-24-077012 · ownership.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-06-20

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0000950170-24-066144 · ownership.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,876

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25, and November 25 of each year.

SEC source: 0000950170-24-066144 · ownership.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 789,303

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-24-004041 · doc4.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,095

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-24-004041 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 764,084

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-056840 · doc4.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,314

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-23-056840 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 738,865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-047671 · doc4.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,533

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-23-047671 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 713,646

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-036024 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-06-08

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001209191-23-032711 · doc4.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 201,752

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-23-032711 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 688,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-23-013871 · doc4.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,971

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-23-013871 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 663,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-058970 · doc4.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,190

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F2 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F2 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-058970 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 637,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-047947 · doc4.xml · nonDerivative · entry 2

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 612,770

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 13,379 shares sold in the price range of $4.01 to $4.02 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-047947 · doc4.xml · derivative · entry 4

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,409

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-047947 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 626,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-049125 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-07-07

F1 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on July 8, 2023.

SEC source: 0001209191-22-032673 · doc4.xml · nonDerivative · entry 2

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,930

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 13,162 shares sold in the price range of $1.90 to $1.95 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-032673 · doc4.xml · derivative · entry 4

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,628

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-032673 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 614,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-22-020076 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 412,500

Underlying: Common Stock · 412,500 shares

Expires 2032-03-17

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date.

SEC source: 0001209191-22-014442 · doc4.xml · nonDerivative · entry 2

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 588,873

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 14,365 shares sold in the price range of $2.7101 to $2.84 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-22-014442 · doc4.xml · derivative · entry 4

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 327,847

Underlying: Common Stock · 25,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F4 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F4 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-22-014442 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 603,508

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-21-071641 · doc4.xml · derivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,800

Underlying: Common Stock · 7,000 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the Shares subject to the Option shall vest on the one (1) month anniversary of February 13, 2019 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider in accordance with the Plan through each such date.

SEC source: 0001209191-21-071641 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 578,289

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-067044 · doc4.xml · nonDerivative · entry 3

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 571,289

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F4 · price: Represents the weighted average share price of an aggregate total of 15,833 shares sold in the price range of $4.62 to $5.34 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-067044 · doc4.xml · nonDerivative · entry 2

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 587,122

F2 · kind: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F3 · price: Represents the weighted average share price of an aggregate total of 11,914 shares sold in the price range of $4.7150 to $5.01 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001209191-21-067044 · doc4.xml · derivative · entry 5

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 353,066

Underlying: Common Stock · 50,437 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

F5 · derivative.exercise_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

F5 · derivative.expiration_date: One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the "First Vesting Date"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the "Plan") through the applicable vesting date. For the purposes of the foregoing, "Quarterly Vesting Date" means February 25, May 25, August 25,and November 25 of each year.

SEC source: 0001209191-21-067044 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 599,036

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

SEC source: 0001209191-21-064540 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 548,599

SEC source: 0001209191-21-047385 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-07-15

F1 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on July 16, 2022.

SEC source: 0001209191-21-023641 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,993

Underlying: Common Stock · 441,993 shares

Expires 2031-03-26

F1 · derivative.exercise_date: One forty-eighth (1/48th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 26, 2021 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date.

SEC source: 0001209191-20-035208 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

Underlying: Common Stock · 500 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on June 5, 2021.

SEC source: 0001209191-19-038013 · doc4.xml · derivative · entry 2

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

Underlying: Common Stock · 500 shares

Expires 2029-06-16

F2 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on June 17, 2020.

SEC source: 0001209191-19-038013 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-04-29

F1 · derivative.exercise_date: The option was granted on 4/30/19, but was contingent on shareholder approval of an increase in the shares issuable under the Issuer's 2013 Amended and Restated Equity Incentive Plan at the Issuer's annual meeting of stockholders held on 6/17/19, and therefore for purposes of Section 16 the option was not "acquired" until such stockholder approval was obtained. 25% of the shares subject to the option shall vest on the first annual anniversary of the Vesting Commencement Date (4/30/19) with the balance vesting in equal monthly installments thereafter until fully vested on 4/30/23

SEC source: 0001209191-18-040345 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-28

F1 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on June 28, 2019.

SEC source: 0001209191-17-037237 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-05-30

F1 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on May 2, 2018.

SEC source: 0001209191-17-024283 · doc4.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,166

Underlying: Common Stock · 4,166 shares

Expires 2027-03-30

F1 · derivative.exercise_date: The shares subject to the option shall be 100% vested and exercisable on June 28, 2017.

SEC source: 0001562180-17-001301 · primarydocument.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 625,545

F1 · ownership.nature: The securities are owned directly by Forward Ventures V, LP ("Forward V"), Forward Ventures IV, LP ("Forward IV") and Forward Ventures IVB, LP ("Forward IVB" and collectively, the "Forward Entities"). Dr. Royston is a member of Forward V and a managing member of Forward IV Associates, LLC which is the general partner of each of Forward IV and Forward IVB. As a result, Dr. Royston shares voting and investment power over the shares owned by the Forward Entities. Dr. Royston disclaims beneficial ownership of all shares held by the Forward Entities, except to the extent of his actual pecuniary interest therein.

SEC source: 0001562180-16-003355 · primarydocument.xml · derivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2026-10-31

F1 · derivative.exercise_date: One hundred percent (100%) of the total number of shares underlying the option shall vest on October 31, 2017, subject to the reporting person's continuous service through the vesting date.

SEC source: 0001209191-17-023533 · doc4.xml · nonDerivative · entry 1

ROYSTON IVOR · CIK 0001026765 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,294

F1 · shares: On September 27, 2016, the Issuer effected a 1-for-3 reverse stock split resulting in the reporting person's ownership of 34,584 fewer shares.

F2 · shares: The number of shares and purchase price shown in column 4 above are reflected on a post-split basis.

F1 · price: On September 27, 2016, the Issuer effected a 1-for-3 reverse stock split resulting in the reporting person's ownership of 34,584 fewer shares.

F2 · price: The number of shares and purchase price shown in column 4 above are reflected on a post-split basis.

F1 · balance_after: On September 27, 2016, the Issuer effected a 1-for-3 reverse stock split resulting in the reporting person's ownership of 34,584 fewer shares.

F3 · balance_after: The number of shares reflected in column 5 above reflects the Reporting Person's ownership as of March 29, 2017.